Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Price and Financial Metrics


Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): $148.53

-1.00 (-0.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JAZZ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

JAZZ POWR Grades


  • JAZZ scores best on the Value dimension, with a Value rank ahead of 88.53% of US stocks.
  • The strongest trend for JAZZ is in Growth, which has been heading up over the past 179 days.
  • JAZZ ranks lowest in Momentum; there it ranks in the 12th percentile.

JAZZ Stock Summary

  • JAZZ has a higher market value than 81.03% of US stocks; more precisely, its current market capitalization is $9,763,997,704.
  • With a year-over-year growth in debt of 174.61%, Jazz Pharmaceuticals plc's debt growth rate surpasses 93.81% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for JAZZ comes in at -39.28% -- higher than that of only 10.82% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Jazz Pharmaceuticals plc are SCOR, GLBE, BDSX, CMTL, and ABMD.
  • Visit JAZZ's SEC page to see the company's official filings. To visit the company's web site, go to www.jazzpharma.com.

JAZZ Valuation Summary

  • In comparison to the median Healthcare stock, JAZZ's price/sales ratio is 72.69% lower, now standing at 3.1.
  • Over the past 174 months, JAZZ's price/sales ratio has gone down 5.8.
  • Over the past 174 months, JAZZ's EV/EBIT ratio has gone up 40.4.

Below are key valuation metrics over time for JAZZ.

Stock Date P/S P/B P/E EV/EBIT
JAZZ 2021-08-31 3.1 1.9 200.5 30.0
JAZZ 2021-08-30 3.1 1.9 200.3 30.0
JAZZ 2021-08-27 3.1 2.0 202.7 30.2
JAZZ 2021-08-26 3.1 2.0 202.4 30.2
JAZZ 2021-08-25 3.1 2.0 205.9 30.5
JAZZ 2021-08-24 3.2 2.0 207.7 30.6

JAZZ Growth Metrics

    The 3 year revenue growth rate now stands at 44.62%.
  • The 4 year price growth rate now stands at -25.31%.
  • Its 5 year net cashflow from operations growth rate is now at 46.28%.
Over the past 15 months, JAZZ's revenue has gone up $814,448,000.

The table below shows JAZZ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 3,094.238 778.507 -329.668
2021-09-30 2,863.024 787.023 -160.903
2021-06-30 2,625.797 770.852 40.164
2021-03-31 2,436.422 911.676 518.281
2020-12-31 2,363.567 899.648 238.616
2020-09-30 2,279.79 801.175 179.194

JAZZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JAZZ has a Quality Grade of C, ranking ahead of 58.49% of graded US stocks.
  • JAZZ's asset turnover comes in at 0.32 -- ranking 143rd of 680 Pharmaceutical Products stocks.
  • REGN, AGLE, and NTLA are the stocks whose asset turnover ratios are most correlated with JAZZ.

The table below shows JAZZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.320 0.904 0.095
2021-03-31 0.380 0.934 0.196
2020-12-31 0.392 0.937 0.103
2020-09-30 0.395 0.941 0.076
2020-06-30 0.397 0.944 0.064
2020-03-31 0.402 0.944 0.073

JAZZ Price Target

For more insight on analysts targets of JAZZ, see our JAZZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $207.82 Average Broker Recommendation 1.37 (Strong Buy)

JAZZ Stock Price Chart Interactive Chart >

Price chart for JAZZ

JAZZ Price/Volume Stats

Current price $148.53 52-week high $189.00
Prev. close $149.53 52-week low $117.64
Day low $144.93 Volume 375,700
Day high $150.52 Avg. volume 600,083
50-day MA $157.49 Dividend yield N/A
200-day MA $141.07 Market Cap 9.26B

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Company Bio


Jazz Pharmaceuticals is an international biopharmaceutical company with a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. The company was founded in 2003 and is based in Dublin, Ireland.


JAZZ Latest News Stream


Event/Time News Detail
Loading, please wait...

JAZZ Latest Social Stream


Loading social stream, please wait...

View Full JAZZ Social Stream

Latest JAZZ News From Around the Web

Below are the latest news stories about Jazz Pharmaceuticals plc that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.

Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 25, 2022

Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and full year financial results on Tuesday, March 1, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2021 fourth quarter and full year financial results and provide a business and financial update.

Yahoo | February 15, 2022

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

Is Jazz Pharmaceuticals (JAZZ) Stock a Suitable Value Pick Now?

Let's see if Jazz Pharmaceuticals plc (JAZZ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Yahoo | February 11, 2022

Jazz Pharmaceuticals (JAZZ) Received its Third Buy in a Row

After Leerink Partners and BMO Capital gave Jazz Pharmaceuticals (NASDAQ: JAZZ) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Ami Fadia reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $215.00. The company's shares closed last Friday at $140.94. According to TipRanks.com, Fadia is a 1-star analyst with an average return of -2.8% and a 40.3% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $202.

Howard Kim on TipRanks | February 7, 2022

Read More 'JAZZ' Stories Here

JAZZ Price Returns

1-mo -10.28%
3-mo 7.72%
6-mo 14.77%
1-year -17.48%
3-year 5.40%
5-year -2.26%
YTD 16.59%
2021 -22.81%
2020 10.56%
2019 20.43%
2018 -7.94%
2017 23.50%

Continue Researching JAZZ

Here are a few links from around the web to help you further your research on Jazz Pharmaceuticals plc's stock as an investment opportunity:

Jazz Pharmaceuticals plc (JAZZ) Stock Price | Nasdaq
Jazz Pharmaceuticals plc (JAZZ) Stock Quote, History and News - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0502 seconds.